The immunogenicity of a cetuximab-treated mouse CRC cell line (CT26) expressing human EGFR (hEGFR-CT26) increased and the tumor cells induced an effective anti-tumor response (Pozzi et al., 2016). The gene discussed is DDX53; the disease is neoplasm.